Get to know our clinical trials

Trial of intravenous prasinezumab in participants with incipient parkinson's disease.

THE OBJECTIVE OF THIS STUDY IS TO COMPARE THE EFFECTS, POSITIVE OR NEGATIVE, OF PRASINEZUMAB VERSUS PLACEBO IN PATIENTS WITH INCIPIENT PARKINSON'S DISEASE WHO ARE TAKING REGULAR MEDICATION TO CONTROL THE SYMPTOMS OF THE DISEASE. IN THIS STUDY YOU WILL RECEIVE PRASINEZUMAB OR PLACEBO. A PLACEBO LOOKS LIKE A DRUG, BUT DOES NOT CONTAIN ANY ACTIVE INGREDIENT.

Status
In recruitment
headquarters
Pamplona

Technical Summary

  • PHASE IIB, RANDOMIZED, DOUBLE-MASKED, PLACEBO-COMPARATIVE, MULTICENTER, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS PRASINEZUMAB IN PARTICIPANTS WITH INCIPIENT PARKINSON'S DISEASE. IMMUNOTHERAPY
  • Code EudraCT: 2020-004997-23
  • Protocol number: BN42358
  • Promoter: Roche Farma, S.A.
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.